ClinicalTrials.gg
RecruitingNCT06723275LEOPARD PVC1Updated Jul 29, 2026

LEOPARD Prospective Validation Cohort 1

An observational study in Decompensated Liver Cirrhosis, Primary Biliary Cholangitis and Primary Sclerosing Cholangitis, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 8 sites in 5 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
630
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Liver Cirrhosis, Biliary with a site in France — 4 open to participants now, 7 under way, 4 of them phase 3. Liver Cirrhosis, Biliary · France.

Started
2026
the only one that year
Observational
4 of 26
2 open now
Registered
25th of 26
by date
Lead sponsor
3 of 26
Assistance Publique - Hôpitaux de Paris

Among the 26 studies in Liver Cirrhosis, Biliary with a site in France, this one is the only one that started in 2026, is one of 4 observational ones, and was the 25th registered.

Liver Cirrhosis, Biliary

214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.

Browse Liver Cirrhosis, Biliary studies →

Open to participants now

4 of the 26 studies in Liver Cirrhosis, Biliary with a site in France are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Liver Cirrhosis, Biliary with a site in France, or all of them as a file.
02

Study summary

Intro:

The present clinical research protocol is part of the LEOPARD European project (Grant n° 101080964 Horizon Europe) which aims to design and validate new predictive models of mortality among liver transplantation (LT) candidates.

MELD based-liver graft allocation systems have become increasingly inaccurate over the last decade to predict mortality/dropout of liver transplantation (LT) candidates on the waitlist (WL). Wide disparities in mortality/dropout on the WL also exist across European countries, ranging from 5 to 30% according to transplantation indications. In this setting, the European Commission- Horizon Europe funded-LEOPARD project intends to design new, 2nd generation, AI-machine learning-based predictive models of delisting in LT candidates, to better serve on time patients with the highest risk of dropout on the WL and to improve equity of access to LT across Europe.

Hypothesis/Objective The scientific justification of the LEOPARD PVC1 is therefore

  1. to build an external cohort of LT candidates to test and validate the LEOPARD models, therefore providing robust evidence for adoption of LEOPARD models by Organ Sharing Organizations (OSOs).
  2. to collect granular data, bio- and tissues sampes and images to test last-generation OMICs predictors and radiomics, therefore opening the door to design of 3rd generation, precision medicine-based predictive models.

The primary objective of the LEOPARD longitudinal study is to test and validate AI-based 2nd generation LEOPARD predictive models of mortality/drop out on the waitlist in patients with decompensated cirrhosis, or other end-stage chronic liver diseases, and in patients listed for HCC.

Method Multicenter Prospective longitudinal study in up to 630 enrolments (in case of replacing participants after inclusion) to obtain 600 patients meeting selection criteria, in 30 hospitals in 5 European countries including France, Italy, The Netherlands, Belgium and Germany.

03

Conditions studied

  • Decompensated Liver Cirrhosis
  • Primary Biliary Cholangitis
  • Primary Sclerosing Cholangitis
  • Hepato-cellular Carcinoma

Keywords

  • Liver transplantation
  • Predictive models
  • Liver transplantation candidates
  • prospective longitudinal study
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients consecutively listed for LT for end-stage chronic liver diseases and HCC

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult [age 18;70] patients listed for:

    • decompensated cirrhosis as primary diagnosis, irrespective of liver disease etiology (subset1) OR
    • other end-stage liver diseases requiring LT, listed under MELD offering schemes (subset 2), including notably but not exclusively cholestatic diseases, primary biliary cholangitis, primary sclerosing cholangitis (subset 2) OR
    • HCC as primary diagnosis, whatever the etiology of the underlying liver disease with or without underlying cirrhosis (subset 3). (HCC diagnosed on Barcelona/EASL criteria or proven. HCC meeting or not Milan criteria, as per center practice.)
  • Patients registered on national waiting lists under the MELD offering schemes, regardless of extra MELD points are affected or not.
  • Patient (or trusted person, family member or close relation, if the patient is unable to express consent) who has been informed and signed the .
  • Patient affiliated with a health insurance scheme (beneficiary or entitled party).

Exclusion criteria

Exclusion Criteria:

  • Tumor vascular invasion (portal or hepatic veins) evidenced by imaging on pre transplantation work-up, including PVT stage 1
  • Extra-hepatic of HCC, as assessed by sectional imaging, functional imaging (18 FDG PET CT/MRI) or proven
  • Women who are pregnant or nursing
  • Patients who are under safeguard of justice or tutorship or curatorship
  • Patient on AME (state medical aid)
  • Participation in another trial including other studies proposed as part of the European LEOPARD project (cohort associated to WP1 \& WP5 ("LEOPARD TVDCS") or being in the exclusion period following previous interventional research involving the human person, if applicable
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
630 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Subset 1

    Decompensated cirrhosis as primary diagnosis, irrespective of liver disease etiology

    Other: Standardized assessments and biobanking

  • Subset 2

    Other chronic end-stage liver diseases requiring LT, listed under MELD offering schemes, including notably but not exclusively cholestatic diseases, primary biliary cholangitis, primary sclerosing cholangitis

    Other: Standardized assessments and biobanking

  • Subset 3

    Hepato-cellular carcinoma as primary diagnosis, whatever the etiology of the underlying liver disease with or without underlying cirrhosis

    Other: Standardized assessments, guided tumor biopsy and biobanking

Interventions

  • OtherStandardized assessments, guided tumor biopsy and biobanking

    Standardized assessment of Scores * Guided tumor biopsy in patients listed for hepatocellular carcinoma with active tumor at listing in centers not perfoming tumor biopsy on a routine basis * Additional blood sampling for biobanking and subsequent analysis of innovative biomarkers and OMICs * Urine sampling for biobanking and subsequent analysis of innovative biomarkers * Ascite sampling for biobanking and subsequent analysis * Tumor sampling for biobanking and subsequent analysis * Centralized assay for routine biomarkers

  • OtherStandardized assessments and biobanking

    * Standardized assessment of Scores * Additional blood sampling for biobanking and subsequent analysis of innovative biomarkers and OMICs * Urine sampling for biobanking and subsequent analysis of innovative biomarkers * Ascite sampling for biobanking and subsequent analysis * Tumor sampling for biobanking and subsequent analysis * Centralized assay for routine biomarkers

06

What researchers measure

Primary outcomes

  1. Clinical primary endpoint will be a composite of mortality or drop out for being too sick on transplantation waiting list, since kinetics of dropout differs according to LT indications

    * 3-month mortality/dropout for being too sick after listing in subsets 1 and 2 * 12-month mortality/dropout for being too sick (tumor progression) after listing in subset 3

    Time frame: 3 months after listing in subsets 1 & 2 ; 12 months after listing in subset 3

Secondary outcomes

  1. Number of participants with 6-month mortality/dropout for being too sick (subsets 1 to 3)

    Mortality/Drop out for being too sick (subsets 1 to 3)

    Time frame: 6 months after listing

  2. Number of participants with 9-month mortality/dropout for too sick in subsets 1, 2

    Mortality/dropout for being too sick

    Time frame: 9 months after listing

  3. Number of participants with 12-month mortality/dropout for too sick in subset 3

    Mortality/dropout for being too sick

    Time frame: 12 months after listing

  4. Causes of death/drop-out for being too sick

    Causes of death/drop-out

    Time frame: From date of inclusion until date of death from any cause or date of drop-out for being too sick, whichever came first, assessed up to 12 months

  5. Incidence of delisting for patient's decision or clinical improvement

    Delisting for patient's decision or clinical improvement

    Time frame: From date of inclusion until date of delisting for patient's decision or clinical improvement, assessed up to12 months

  6. Time from listing to death/drop-out

    Duration from listing to death/dropout (days)

    Time frame: From date of listing until date of death from any cause or date of drop-out for being too sick, whichever came first, assessed up to 12 months

  7. Time to transplantation

    Duration from listing to transplantation (days)

    Time frame: From date of listing until date of transplantation, assessed up to 12 months

  8. Number of participants with 1-year post transplant survival in subsets 1-2

    Survival in subsets 1-2

    Time frame: 12 months after liver transplantation

  9. Number of participants with 9-month HCC recurrence in subset 3

    HCC recurrence in subset 3

    Time frame: 9 months after liver transplantation

  10. Number of participants with 9-month post transplant survival in subset 3

    Post transplant survival in subset 3

    Time frame: 9 months after liver transplantation

  11. 9-month and 12-month transplant benefit in subsets 3 and 1-2, respectively

    Relevant comorbidities

    Time frame: 9 months and 12 months after liver transplantation

07

Study locations

4 of 8 sites recruiting
  • Department of Gastroenterology and Hepatology Universitair Ziekenhuis Gent
    Ghent, Belgium, Belgium
    Not yet recruiting
    • Xavier Verhelst, MD-PHD · Contact
  • Beaujon Hospital, Department of Hepatology
    Clichy, France 92110, France
    Recruiting
  • Hospital Henri Mondor, Department of Hepatology
    Créteil, France 94010, France
    Recruiting
  • St Eloi Hospital, Department of Hepato-gastro-enterology,
    Montpellier, France 34295, France
    Recruiting
  • Hospital La Pitié Salpêtrière, Department of Hepato-gastro-enterology
    Paris, France 75013, France
    Recruiting
  • Universitätsklinikum Schleswig - Holstein | UKSH · Transplantation Medicine
    Kiel, Germany, Germany
    Not yet recruiting
    • Felix Braun, MD-PHD · Contact
  • Italian National Transplant Center
    Roma, Italy, Italy
    Not yet recruiting
    • Silvia Trapani, MD · Contact
  • Center for Liver Tumors Leiden of the Leiden University Medical Center (LUMC)
    Leiden, Netherlands, Netherlands
    Not yet recruiting
    • Minneke Coenraad, MD-PHD · Contact
08

References and documents

Individual participant data

Plan to share: No — DATAS ARE OWN BY ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, PLEASE CONTACT SPONSOR FOR FURTHER INFORMATION

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Jul 2028, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2024
First posted
Dec 9, 2024
StartActual
Jul 7, 2026
Primary completionEst.
Jul 7, 2028
CompletionEst.
Apr 7, 2029
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06723275
Collaborators
University of Luxembourg, Hospital Universitario La Fe, ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK (ECRIN), Ophiomics - Precision Medicine, EF CLIF, INSERM 1149, Institut National de la Santé Et de la Recherche Médicale, France
Responsible party
Sponsor
First posted
Dec 9, 2024
Start date
Jul 7, 2026
Primary completion
Jul 7, 2028 (estimated)
Completion
Apr 7, 2029 (estimated)
Last update
Jul 29, 2026

Study contacts

Christophe DUVOUX, MD-PHD
Contact
christophe.duvoux@aphp.fr
01 49 81 23 25 ext. +33
Nihel BERREBEH, Project Manager
Contact
nihel.berrebeh@aphp.fr
01 40 27 46 20 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion